EcoDrugPlus

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSPLAG00000021745
Gene Symbol: HTR5A
3 Cross references
209 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSPLAG00000023598
Gene Symbol: HTR6
3 Cross references
114 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSPLAG00000005759
Gene Symbol: HTR7
3 Cross references
195 Possible Orthologues:

5-Hydroxytryptamine Receptor 7-Like

Ensembl ID : ENSPLAG00000014586
Gene Symbol: LOC106938992
3 Cross references
195 Possible Orthologues:

60s Ribosomal Protein L19

Ensembl ID : ENSPLAG00000016579
Gene Symbol: LOC106949754
4 Cross references
333 Possible Orthologues:

60s Ribosomal Protein L19

Ensembl ID : ENSPLAG00000002433
Gene Symbol: LOC106953278
3 Cross references
334 Possible Orthologues:

60s Ribosomal Protein L22-Like

Ensembl ID : ENSPLAG00000005259
Gene Symbol: LOC106947888
2 Cross references
198 Possible Orthologues:

60s Ribosomal Protein L26

Ensembl ID : ENSPLAG00000017267
Gene Symbol: LOC106953469
3 Cross references
477 Possible Orthologues:

60s Ribosomal Protein L3

Ensembl ID : ENSPLAG00000014335
Gene Symbol: LOC106962427
3 Cross references
335 Possible Orthologues:

60s Ribosomal Protein L39

Ensembl ID : ENSPLAG00000005117
Gene Symbol: LOC106940246
3 Cross references
170 Possible Orthologues:

60s Ribosomal Protein L5

Ensembl ID : ENSPLAG00000010948
Gene Symbol: LOC106962907
3 Cross references
455 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSPLAG00000019491
Gene Symbol: ARAF
3 Cross references
191 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).